CN113827606A - Application of raw onionsoside A in preparation of medicine for treating liver cell and liver cancer - Google Patents
Application of raw onionsoside A in preparation of medicine for treating liver cell and liver cancer Download PDFInfo
- Publication number
- CN113827606A CN113827606A CN202010584016.7A CN202010584016A CN113827606A CN 113827606 A CN113827606 A CN 113827606A CN 202010584016 A CN202010584016 A CN 202010584016A CN 113827606 A CN113827606 A CN 113827606A
- Authority
- CN
- China
- Prior art keywords
- liver cancer
- raw
- treating
- onionsoside
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 201000007270 liver cancer Diseases 0.000 title claims abstract description 41
- 208000014018 liver neoplasm Diseases 0.000 title claims abstract description 41
- 239000003814 drug Substances 0.000 title claims abstract description 40
- 210000005229 liver cell Anatomy 0.000 title abstract description 8
- 238000002360 preparation method Methods 0.000 title abstract description 5
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims abstract description 29
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims abstract description 21
- 229940079593 drug Drugs 0.000 claims abstract description 16
- 230000006907 apoptotic process Effects 0.000 claims abstract description 14
- 229940002612 prodrug Drugs 0.000 claims abstract description 7
- 239000000651 prodrug Substances 0.000 claims abstract description 7
- MYEJFUXQJGHEQK-ALRJYLEOSA-N Proscillaridin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1C=C2CC[C@H]3[C@@]4(O)CC[C@H](C5=COC(=O)C=C5)[C@@]4(C)CC[C@@H]3[C@@]2(C)CC1 MYEJFUXQJGHEQK-ALRJYLEOSA-N 0.000 claims abstract description 6
- 239000003937 drug carrier Substances 0.000 claims abstract description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 4
- 108010050808 Procollagen Proteins 0.000 claims description 12
- 230000022131 cell cycle Effects 0.000 claims description 2
- 230000010261 cell growth Effects 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 abstract description 41
- 206010028980 Neoplasm Diseases 0.000 abstract description 16
- XUHLIQGRKRUKPH-GCXOYZPQSA-N Alliin Natural products N[C@H](C[S@@](=O)CC=C)C(O)=O XUHLIQGRKRUKPH-GCXOYZPQSA-N 0.000 abstract description 9
- XUHLIQGRKRUKPH-UHFFFAOYSA-N S-allyl-L-cysteine sulfoxide Natural products OC(=O)C(N)CS(=O)CC=C XUHLIQGRKRUKPH-UHFFFAOYSA-N 0.000 abstract description 9
- XUHLIQGRKRUKPH-DYEAUMGKSA-N alliin Chemical compound OC(=O)[C@@H](N)C[S@@](=O)CC=C XUHLIQGRKRUKPH-DYEAUMGKSA-N 0.000 abstract description 9
- 235000015295 alliin Nutrition 0.000 abstract description 9
- 238000002474 experimental method Methods 0.000 abstract description 9
- 201000011510 cancer Diseases 0.000 abstract description 8
- 229960003584 proscillaridin Drugs 0.000 abstract description 4
- MYEJFUXQJGHEQK-UHFFFAOYSA-N proscillaridin A Natural products OC1C(O)C(O)C(C)OC1OC1C=C2CCC3C4(O)CCC(C5=COC(=O)C=C5)C4(C)CCC3C2(C)CC1 MYEJFUXQJGHEQK-UHFFFAOYSA-N 0.000 abstract description 4
- 230000000694 effects Effects 0.000 description 14
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- PYXFVCFISTUSOO-HKUCOEKDSA-N (20S)-protopanaxadiol Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@H]([C@@](C)(O)CCC=C(C)C)[C@H]4[C@H](O)C[C@@H]3[C@]21C PYXFVCFISTUSOO-HKUCOEKDSA-N 0.000 description 7
- 241000700159 Rattus Species 0.000 description 7
- PYXFVCFISTUSOO-UHFFFAOYSA-N betulafolienetriol Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC(C(C)(O)CCC=C(C)C)C4C(O)CC3C21C PYXFVCFISTUSOO-UHFFFAOYSA-N 0.000 description 7
- 230000004663 cell proliferation Effects 0.000 description 7
- 210000003494 hepatocyte Anatomy 0.000 description 7
- SWQINCWATANGKN-UHFFFAOYSA-N protopanaxadiol Natural products CC(CCC=C(C)C)C1CCC2(C)C1C(O)CC1C3(C)CCC(O)C(C)(C)C3CCC21C SWQINCWATANGKN-UHFFFAOYSA-N 0.000 description 7
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 5
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 5
- 229960003787 sorafenib Drugs 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 4
- 230000003833 cell viability Effects 0.000 description 4
- 238000011580 nude mouse model Methods 0.000 description 4
- 150000008143 steroidal glycosides Chemical class 0.000 description 4
- YSCJAYPKBYRXEZ-HZPINHDXSA-N (2s,3s,4s,5r,6r)-6-[[(3s,4ar,6ar,6bs,8as,12as,14ar,14br)-4,4,6a,6b,11,11,14b-heptamethyl-8a-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxycarbonyl-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl]oxy]-3-hydroxy-4-[(2s,3r,4s, Chemical compound O([C@H]1[C@H](O)[C@H](O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@]1(CCC(C[C@H]14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C(O)=O)[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O YSCJAYPKBYRXEZ-HZPINHDXSA-N 0.000 description 3
- 241000234282 Allium Species 0.000 description 3
- 235000002732 Allium cepa var. cepa Nutrition 0.000 description 3
- 241000699660 Mus musculus Species 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 238000005206 flow analysis Methods 0.000 description 3
- 230000009036 growth inhibition Effects 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 2
- 101000600434 Homo sapiens Putative uncharacterized protein encoded by MIR7-3HG Proteins 0.000 description 2
- 239000005820 Prochloraz Substances 0.000 description 2
- 102100037401 Putative uncharacterized protein encoded by MIR7-3HG Human genes 0.000 description 2
- 230000001640 apoptogenic effect Effects 0.000 description 2
- 229940097217 cardiac glycoside Drugs 0.000 description 2
- 239000002368 cardiac glycoside Substances 0.000 description 2
- 230000033366 cell cycle process Effects 0.000 description 2
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 2
- 229960005156 digoxin Drugs 0.000 description 2
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- LPMXVESGRSUGHW-HBYQJFLCSA-N ouabain Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1C[C@@]2(O)CC[C@H]3[C@@]4(O)CC[C@H](C=5COC(=O)C=5)[C@@]4(C)C[C@@H](O)[C@@H]3[C@@]2(CO)[C@H](O)C1 LPMXVESGRSUGHW-HBYQJFLCSA-N 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- TVLSRXXIMLFWEO-UHFFFAOYSA-N prochloraz Chemical compound C1=CN=CN1C(=O)N(CCC)CCOC1=C(Cl)C=C(Cl)C=C1Cl TVLSRXXIMLFWEO-UHFFFAOYSA-N 0.000 description 2
- QXJKBPAVAHBARF-BETUJISGSA-N procymidone Chemical compound O=C([C@]1(C)C[C@@]1(C1=O)C)N1C1=CC(Cl)=CC(Cl)=C1 QXJKBPAVAHBARF-BETUJISGSA-N 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 229930002534 steroid glycoside Natural products 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- TWCMVXMQHSVIOJ-UHFFFAOYSA-N Aglycone of yadanzioside D Natural products COC(=O)C12OCC34C(CC5C(=CC(O)C(O)C5(C)C3C(O)C1O)C)OC(=O)C(OC(=O)C)C24 TWCMVXMQHSVIOJ-UHFFFAOYSA-N 0.000 description 1
- PLMKQQMDOMTZGG-UHFFFAOYSA-N Astrantiagenin E-methylester Natural products CC12CCC(O)C(C)(CO)C1CCC1(C)C2CC=C2C3CC(C)(C)CCC3(C(=O)OC)CCC21C PLMKQQMDOMTZGG-UHFFFAOYSA-N 0.000 description 1
- 241000219193 Brassicaceae Species 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 240000001879 Digitalis lutea Species 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 239000002138 L01XE21 - Regorafenib Substances 0.000 description 1
- 241000234280 Liliaceae Species 0.000 description 1
- 241000218231 Moraceae Species 0.000 description 1
- 241000207834 Oleaceae Species 0.000 description 1
- 108010087230 Sincalide Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000362 adenosine triphosphatase inhibitor Substances 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 239000003560 cancer drug Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000010609 cell counting kit-8 assay Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- -1 digoxin Chemical compound 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- PFOARMALXZGCHY-UHFFFAOYSA-N homoegonol Natural products C1=C(OC)C(OC)=CC=C1C1=CC2=CC(CCCO)=CC(OC)=C2O1 PFOARMALXZGCHY-UHFFFAOYSA-N 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 239000010413 mother solution Substances 0.000 description 1
- 231100001083 no cytotoxicity Toxicity 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 229960003343 ouabain Drugs 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 229960004836 regorafenib Drugs 0.000 description 1
- FNHKPVJBJVTLMP-UHFFFAOYSA-N regorafenib Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=C(F)C(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 FNHKPVJBJVTLMP-UHFFFAOYSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 230000005909 tumor killing Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention belongs to the technical field of biological medicines, relates to a new pharmaceutical application of procheilin A, and particularly relates to an application of procheilin A (Proscillaridin A) (CAS466-06-8) in preparation of a medicine for treating liver cancer, particularly hepatocellular carcinoma (HCC). Experiments show that the alliin A can obviously inhibit the growth of liver cancer cells and promote the apoptosis of the liver cancer cells, and the alliin A can be used as a prodrug to prepare a medicament for treating liver cancer, particularly liver cell cancer, and a pharmaceutical composition containing the alliin A or the alliin A as the prodrug and a pharmaceutically acceptable carrier for treating the liver cancer, particularly the liver cell cancer.
Description
Technical Field
The invention belongs to the technical field of biological medicines, relates to a new pharmaceutical application of prochloraz A, and particularly relates to an application of prochloraz A (CAS466-06-8) in preparation of a medicine for treating liver cancer, in particular to hepatocellular carcinoma (HCC).
Background
The prior art discloses hepatocellular carcinoma (HCC for short) as one of the most common malignant tumors in China and even all over the world, which seriously harms human health. According to the latest data of global cancer statistics, HCC has become one of ten gross death malignant tumors worldwide, male death patients are obviously more than female, more than 50% of new onset and death cases occur in China, and the mortality rate of HCC morbidity shows the trend that rural areas are higher than urban areas and male are higher than female.
Studies have shown that the development of HCC is associated with a number of factors, such as hepatitis virus infection, long-term alcohol intake, etc. At present, the treatment of HCC is mainly surgical treatment, sorafenib and regorafenib are the only existing drugs approved by FDA to treat HCC, however, sorafenib has less than 3 months of overall survival gain for patients with advanced liver cancer, and therefore, the search for other drugs targeting HCC is of great significance. Cardiac glycoside compounds are organic compounds mainly distributed in more than one hundred plants of more than ten families, such as oleaceae, liliaceae, cruciferae, Moraceae and the like, and are formed by combining an alcohol group or an alcohol-like group (ligand or aglycone) with different numbers of sugar molecules, and the structures of the compounds are shown in figure 1. Cardiac glycoside compounds are mainly classified into two classes, namely, dienolide (e.g., procymidone A) and digitalis (e.g., digoxin), and the two classes are mainly distinguished by the difference in R structure. Under normal conditions, Na+-K+ATP enzyme can maintain Na inside and outside cells+，K+Relatively stable, cardiac glycoside compounds capable of inhibiting Na+-K+-ATPase activity to reduce Na+Outflow sum K+Internal flow further causes intracellular Ca2+The concentration is increased, thereby improving the conductivity of myocardial cells, acting on the heart and strengthening myocardial contractility, and is mainly used for treating congestive heart failure and arrhythmia.
The cardiac glycoside compounds are used for treating cancers, and no report on the application of the raw onionside A in preparing the medicaments for treating the liver cancer exists so far. Based on the current situation of the prior art, the inventor of the application plans to provide a new pharmaceutical application of the protopanaxadiol A, and particularly relates to an application of the protopanaxadiol A (ProscillaridinA) (CAS466-06-8) in preparing medicines for treating liver cancer, especially liver cell cancer (HCC).
Disclosure of Invention
The invention aims to provide a new pharmaceutical application of protopanaxadiol A based on the current situation of the prior art, and particularly relates to an application of protopanaxadiol A (ProscillaridinA) (CAS466-06-8) in preparation of a medicament for treating liver cancer, in particular hepatocellular carcinoma (HCC).
The invention further aims to provide a medicament for treating liver cancer, in particular liver cell cancer, which takes the proclaim onion glycoside A as a prodrug.
The invention further aims to provide a pharmaceutical composition for treating liver cancer, in particular liver cell cancer, which comprises the procollagenin A or a medicament which takes the procollagenin A as a medicament precursor and a pharmaceutically acceptable carrier.
The structure of the alliin A (ProA) is shown as a formula 1, and the alliin A (ProA) is purchased from Sigma-Aldrich company with the product number R214310 and the specification of 1mg, is light yellow powder,
the molecular weight of the procollagen A is 530.7, the molecular formula is C30H42O8, and CAS 466-06-8.
The invention performs the experiment of the inhibition effect of the procollagen A on the proliferation of the hepatoma cell line cells, researches the toxic effect of the procollagen A on rat primary hepatocytes, performs the experiment of the procollagen A on promoting the apoptosis of the hepatoma cell and the experiment of the procollagen A on reducing the size of tumor of a tumor-bearing nude mouse, and shows that after the treatment of low-concentration medicament, the hepatoma cell obviously generates the growth inhibition effect, and can effectively promote the apoptosis of the hepatoma cell and influence the cell cycle process.
In the embodiment of the invention, the final concentration of the dissolved medicament is 10mM, and the dissolved medicament is stored at minus 80 ℃ for a long time and at minus 20 ℃ for a short time;
the medicine of the invention obviously inhibits cell growth after acting on a liver cancer cell line MHCC 97H;
the medicine of the invention obviously inhibits cell cycle and apoptosis after acting on a liver cancer cell line MHCC 97H;
the drug of the invention has no growth inhibition effect when acting on rat primary hepatocyte PRH.
The invention provides a new pharmaceutical application of procymidone A (Proscillaridin A) (CAS466-06-8), in particular to an application in preparing medicines for treating liver cancer, especially liver cell liver cancer (HCC). The procollagen A can be used as a prodrug to prepare a medicament for treating liver cancer, particularly hepatocellular carcinoma, and a pharmaceutical composition containing the procollagen A or the procollagen A as the prodrug and a pharmaceutically acceptable carrier for treating the hepatocellular carcinoma. The invention provides a new medicine and a method for treating liver cancer, in particular to hepatocellular carcinoma.
Compared with the existing medicament Sorafenib approved to be on the market for treating the advanced hepatocellular carcinoma, the medicament Sorafenib is easy to generate drug resistance, and the effective action concentration of the proto-echinacoside is obviously lower than that of Sorafenib.
Drawings
FIG. 1 is the molecular structural formula of raw onionsoside A.
FIG. 2 is the experimental results of the effect of different concentrations of proconiflorin A on the cell proliferation of liver cancer cell MHCC 97H;
FIG. 3 is the experimental results of the effect of different concentrations of euscaphioside A on the cell proliferation of hepatoma cell Huh 7;
FIG. 4 is the experimental results of the effect of the different concentrations of the raw onionside A on the cell proliferation of the liver cancer cell HepG 2; in FIGS. 2 to 4, the concentration (nM) of protopanaxaroside A is plotted on the abscissa, and the relative cell viability (relative cell viability) is plotted on the ordinate.
FIG. 5 shows the experimental results of the effect of different concentrations of raw onionside A on the proliferation of rat primary hepatocytes (PRH) cells; the concentration of protopanaxaroside A (. mu.M) is plotted on the abscissa, and the relative cell Viability (relative cell Viability) is plotted on the ordinate.
FIG. 6 and FIG. 7 are the flow analysis and the statistical analysis of different concentrations of proclaim onion glycoside A for promoting the apoptosis of MHCC97H of liver cancer cell;
FIG. 8 and FIG. 9 are the flow analysis and the statistical analysis experimental results of the pro-alliin A with different concentrations for promoting the apoptosis of the liver cancer cell Huh 7;
FIG. 10 and FIG. 11 are flow analysis and statistical analysis of the results of different concentrations of the protopanaxadiol A promoting apoptosis of liver cancer cell HepG 2;
in fig. 7, 9 and 11, the abscissa is the concentration of protopanaxacin a (nM), the ordinate is the apoptosis rate, p represents p <0.01, and p represents p < 0.001.
FIG. 12 is a graph showing the comparison of the volume of subcutaneous tumors in mice of the experimental group and the control group in example 4;
fig. 13 is a tumor redistribution graph of subcutaneous tumors of experimental and control mice in example 4, representing p < 0.001.
Detailed Description
In the process of drug screening, the invention discovers that the known chemical substance 'proallicin A' has obvious killing power on liver cancer cells, and can be applied to preparing drugs for treating liver cancer.
The alliin A is named Proscillaridin A by the name of Proscillaridin A and has the molecular formula of C30H42O8, and the specific molecular structure is shown in figure 1. The raw onionside A is odorless, white or nearly white crystal or powder in normal state, is soluble in dimethyl sulfoxide (DMSO), and is not easily soluble in water. Regarding the stability of the substance: in general, in bulk, the solution can be kept stable in light or at 60 deg.C, dissolved in DMSO at room temperature, and the concentration of the mother solution of dissolved procalingin A in DMSO can be adjusted to 10mM, stored at-80 deg.C for a long time, and stored at-20 deg.C for a short time.
As a member of cardiac glycoside drugs, the alliin A is also a Na+/K+ATPase inhibitors, structure, Na+/K+The ATP pump is a heterodimer consisting of an alpha subunit, which functions as a catalyst, and a glycosylated beta subunit. The alpha subunit contains ATP, Na +, K + and cardiac glycoside (e.g., digoxin, G-ouabain) binding sites.
Example 1: experiment of inhibition effect of proclaim onion glycoside A on cell proliferation of liver cancer cell line
Three different hepatoma cells were used in this experiment: MHCC97H, Huh7 and HepG2 cells are paved on a 96-well plate, a control group and six experimental groups according to the cell quantity of 5000 cells/well, each group is repeated for five times, and after 24 hours, a DMEM culture medium is mixed with a medicament to prepare mixed liquid of 10nM, 50nM, 100nM, 500nM, 1000nM and 5000 nM; adding equivalent DMSO into the blank group, respectively adding into each well, detecting the toxic effect of the drug on the cells by using a homonymous CCK-8 end-point method kit after 48 hours, and measuring the absorbance at 450nm by using an enzyme-labeling instrument after 30 minutes;
results as shown in FIGS. 2 to 4, FIG. 2 is a graph showing the experimental results of the effect of different concentrations of proclaitance A on the cell proliferation of MHCC97H of hepatocarcinoma cell; FIG. 3 is the experimental results of the effect of different concentrations of euscaphioside A on the cell proliferation of hepatoma cell Huh 7; fig. 4 is an experimental result of the influence of the procAliside A with different concentrations on the cell proliferation of the liver cancer cell HepG2, and the result shows that the ratio of the experimental group to the control group is smaller and smaller as the concentration of the drug is increased, shows that the number of living cells is sharply reduced as the concentration of the drug is increased, and can be calculated that the procAliside A has obvious toxic effects on various liver cancer cells.
Example 2: toxicity test of Proallicin A on rat Primary hepatocytes
Rat primary hepatocytes were isolated by hepatic venous perfusion of rats (detailed isolation method see doctor wizee thesis "study on molecular mechanism of hepatitis b virus infection model and its early invasion"), collagen-containing 96-well plates were plated and cultured using primary hepatocyte medium, and the remaining implementation methods were the same as the experimental methods described in example 1;
the results are shown in FIG. 5, and the number of viable cells in each experimental group did not decrease significantly compared to the control group at concentrations below 50. mu.M with the increase of the concentration of the protopanaxadiol A, which indicates that there is no cytotoxicity to rat primary hepatocytes under the concentration condition that the protopanaxadiol A has the effect of killing the hepatoma cells in example 1.
Example 3: experiment for promoting apoptosis of liver cancer cells by using procollagen A
And (3) apoptosis: MHCC97H, Huh7 and HepG2 cells were seeded in 12-well plates, and the corresponding concentration of procollagenin A was added, and the same amount of DMSO was added to the blank. Collecting cells after 48 hours, and detecting by using a homozygote apoptosis kit;
as shown in fig. 6 to 11, it is known that apoptotic cells are stained by the dyes anixv and PI, and located in the Q1+ Q2+ Q3 quadrants (fig. 6, 8 and 10), and the number of apoptotic cells increases with increasing drug concentration (fig. 6, 8 and 10), and data statistics (fig. 7, 9 and 11) show that the proapolinoside a can promote apoptosis.
Example 4: experiment for reducing tumor size of tumor-bearing nude mice by using proto-allicin A
MHCC97H cells were resuspended in PBS buffer and then 2X 106The nude mice were inoculated subcutaneously at a concentration of 8 mice per group at a rate of 7mg/kg in the experimental group (sterile aqueous solution of procallin A) one week after cell inoculation, the nude mice were sacrificed 3 weeks after drug injection by injecting sterilized water every three days, and the volumes and tumor weights of the experimental group and the control group were measured;
as shown in fig. 12 and 13, the tumor volume and weight of the experimental group were reduced compared to the control group, demonstrating that the procalillarisin a has a tumor killing effect in mice.
The experimental result of the invention shows that after the treatment of the low-concentration medicament, the liver cancer cell obviously generates growth inhibition effect, and can effectively promote the apoptosis of the liver cancer cell and influence the cell cycle process; the invention provides application of the raw onionsoside A in liver cancer treatment, and further provides a new method and thought for research and development of new liver cancer drugs.
Claims (7)
1. The application of the raw onionsoside A with the structure of the formula 1 in preparing the medicine for treating liver cancer,
the molecular weight of the procollagen A is 530.7, the molecular formula is C30H42O8, and CAS 466-06-8.
2. The use according to claim 1, wherein: the liver cancer is hepatocellular carcinoma.
3. Use according to claim 1 or 2, characterized in that: the final concentration of the dissolved medicine of the raw onionsoside A is 10mM, and the raw onionsoside A is stored at minus 80 ℃ for a long time and at minus 20 ℃ for a short time.
4. Use according to claim 1 or 2, characterized in that: the procollagen A can obviously inhibit cell growth after acting on a liver cancer cell line MHCC 97H.
5. Use according to claim 1 or 2, characterized in that: the procollagen A can obviously inhibit cell cycle and apoptosis after acting on a liver cancer cell line MHCC 97H.
6. A medicament for treating liver cancer, which is characterized in that: the drug comprises the raw onionsoside A as claimed in claim 1 as a prodrug.
7. A pharmaceutical composition for treating liver cancer, which comprises the procallicin a of claim 1 or a drug comprising the procallicin a as a prodrug and a pharmaceutically acceptable carrier.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010584016.7A CN113827606A (en) | 2020-06-23 | 2020-06-23 | Application of raw onionsoside A in preparation of medicine for treating liver cell and liver cancer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010584016.7A CN113827606A (en) | 2020-06-23 | 2020-06-23 | Application of raw onionsoside A in preparation of medicine for treating liver cell and liver cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113827606A true CN113827606A (en) | 2021-12-24 |
Family
ID=78964208
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010584016.7A Pending CN113827606A (en) | 2020-06-23 | 2020-06-23 | Application of raw onionsoside A in preparation of medicine for treating liver cell and liver cancer |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113827606A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060135468A1 (en) * | 2004-09-02 | 2006-06-22 | Bionaut Pharmaceuticals, Inc. | Treatment of refractory cancers using NA+/K+ ATPase inhibitors |
| US20080027010A1 (en) * | 2004-09-02 | 2008-01-31 | Bionaut Pharmaceuticals, Inc. | Treatment of refractory cancers using Na+/K+-ATPase inhibitors |
| CN106714809A (en) * | 2014-08-20 | 2017-05-24 | 耶鲁大学 | Novel compositions and methods useful for treating or preventing liver diseases or disorders, and promoting weight loss |
| CN111132614A (en) * | 2017-07-20 | 2020-05-08 | 路易斯安娜州立大学监测委员会，农业和机械学院 | Targeted osmotic lysis of malignant cancer cells using pulsed magnetic field gradients |
-
2020
- 2020-06-23 CN CN202010584016.7A patent/CN113827606A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060135468A1 (en) * | 2004-09-02 | 2006-06-22 | Bionaut Pharmaceuticals, Inc. | Treatment of refractory cancers using NA+/K+ ATPase inhibitors |
| US20080027010A1 (en) * | 2004-09-02 | 2008-01-31 | Bionaut Pharmaceuticals, Inc. | Treatment of refractory cancers using Na+/K+-ATPase inhibitors |
| CN106714809A (en) * | 2014-08-20 | 2017-05-24 | 耶鲁大学 | Novel compositions and methods useful for treating or preventing liver diseases or disorders, and promoting weight loss |
| CN111132614A (en) * | 2017-07-20 | 2020-05-08 | 路易斯安娜州立大学监测委员会，农业和机械学院 | Targeted osmotic lysis of malignant cancer cells using pulsed magnetic field gradients |
Non-Patent Citations (2)
| Title |
|---|
| HUAFENG ZHANGA等: "Digoxin and other cardiacglycosides inhibit HIF-1alpha synthesis and block tumorgrowth", PNAS, vol. 105, no. 50, pages 19579 * |
| YEONHWA SONG等: "Inhibitors of Na+/K+ ATPase exhibit antitumor effects on multicellular tumor spheroids of hepatocellular carcinoma", 《SCIENTIFIC REPORTS》, vol. 10, no. 1, pages 1 - 16 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Li et al. | Tanshinone IIA and hepatocellular carcinoma: A potential therapeutic drug | |
| CN103179967A (en) | Anti-tumor pharmaceutical composition | |
| CN110585238A (en) | Antitumor drug composition with synergistic effect and application thereof | |
| CN101429201A (en) | Lemon acid berbamine salt, preparation method and application thereof | |
| CN102688493B (en) | Pharmaceutical composition containing resveratrol, resveratrol derivative and Bc1-2 inhibitor, and application thereof | |
| CN101805246B (en) | Urushiol compound and medicinal composition thereof, preparation method and application thereof | |
| CN113925867A (en) | Application of dronedarone hydrochloride and 5-fluorouracil in preparation of antitumor drugs | |
| CN102688489B (en) | Pharmaceutical composition containing triptolide, triptolide derivative and Bc1-2 inhibitor and application thereof | |
| CN108553455A (en) | Application of the three aldehyde radical phloroglucin thiosemicarbazones heterozygote compounds in antitumor drug | |
| CN113827606A (en) | Application of raw onionsoside A in preparation of medicine for treating liver cell and liver cancer | |
| CN104257656B (en) | A kind of collaborative pharmaceutical composition strengthening suppression tumor growth | |
| CN111888370A (en) | Anti-liver cancer medicine prepared from astaxanthin and ginsenoside Rg3 combined composition | |
| CN110946948A (en) | Application of Huafengdan in preparation of anti-breast cancer drugs | |
| CN108295085B (en) | Application of protodioscin in preparation of drug-resistant osteosarcoma drug | |
| US9943560B2 (en) | Medical compositions containing liquorice extracts with synergistic effect | |
| CN103417554B (en) | A kind of antitumor medicine composition and its application | |
| CN105399794A (en) | Fructus momordicae triterpene saponin and salt thereof, preparation method and applications of fructus momordicae triterpene saponin and salt thereof, and pharmaceutical composition containing fructus momordicae triterpene saponin and salt thereof | |
| CN102389559A (en) | Traditional Chinese medicine composition and application as radiotherapy sensitizer | |
| CN102688228B (en) | Pharmaceutical composition containing apigenin, apigenin derivative, rubescensin and rubescensin derivative, and application thereof | |
| CN111821303B (en) | Application of vortioxetine and salts thereof in preparation of antitumor drugs | |
| CN1234353C (en) | Applicaton of gallic acid in prepn. of medicine for antitumor | |
| CN102688490B (en) | Pharmaceutical composition containing evodiamine, evodiamine derivative and Bc1-2 inhibitor, and the application | |
| CN106955292A (en) | A kind of pharmaceutical composition and purposes for treating the cancer of the esophagus | |
| CN115040522B (en) | Medicine for treating lung cancer and preparation method thereof | |
| CN100386089C (en) | Compound lentinan preparation and its preparing method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |